140 related articles for article (PubMed ID: 38449356)
1. Real-world experience of direct oral anticoagulant use in a single pediatric center.
Valenti GG; Sabo C; Hyde M; Rajpurkar M
Pediatr Blood Cancer; 2024 May; 71(5):e30926. PubMed ID: 38449356
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Davis DO; Davis KA
J Pharm Pract; 2018 Oct; 31(5):441-444. PubMed ID: 28803521
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
Coons JC; Albert L; Bejjani A; Iasella CJ
Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of oral anticoagulants in extreme weights.
Chin-Hon J; Davenport L; Huang J; Akerman M; Hindenburg A
Thromb Res; 2023 Nov; 231():1-6. PubMed ID: 37738772
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
[TBL] [Abstract][Full Text] [Related]
9. Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Schaefer JK; Errickson J; Li Y; Kong X; Alexandris-Souphis T; Ali MA; Decamillo D; Haymart B; Kaatz S; Kline-Rogers E; Kozlowski JH; Krol GD; Shankar SR; Sood SL; Froehlich JB; Barnes GD
JAMA Intern Med; 2021 Jun; 181(6):817-824. PubMed ID: 33871544
[TBL] [Abstract][Full Text] [Related]
10. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols.
Draper E; Parkhurst B; Carley B; Krueger K; Larson T; Griesbach S
Am J Cardiovasc Drugs; 2017 Dec; 17(6):475-479. PubMed ID: 28887621
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
13. Just DOAC: Use of direct-acting oral anticoagulants in pediatrics.
Mills K; Hill C; King M; Pauley JL; Cober MP; Fenn NE; Omecene NE; Smith T; Sierra CM
Am J Health Syst Pharm; 2023 Mar; 80(7):412-422. PubMed ID: 36610740
[TBL] [Abstract][Full Text] [Related]
14. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.
Elsebaie MAT; van Es N; Langston A; Büller HR; Gaddh M
J Thromb Haemost; 2019 Apr; 17(4):645-656. PubMed ID: 30690830
[TBL] [Abstract][Full Text] [Related]
16. Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series.
DeCamillo D; Ellsworth S; Kaatz S; Barnes GD
J Thromb Thrombolysis; 2020 Nov; 50(4):844-848. PubMed ID: 32219722
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
18. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
19. Bleeding complications in patients on new oral anticoagulants for venous thromboembolism in Kenya.
Obayo A; Ngunga M; Shah J; Sokwala A; Barasa A
Cardiovasc J Afr; 2022 Jul-Aug 23; 33(4):186-192. PubMed ID: 35118489
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting.
Yassine D; Brown EN; Putney D; Fasoranti O
J Oncol Pharm Pract; 2020 Oct; 26(7):1650-1656. PubMed ID: 32063102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
